Eric Rashba is a Cardiology physician affiliated with Stony Brook Medicine. OpenAlex indexes 130 publications with 1,871 citations (h-index 21); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3001 Expressway Dr N
Islandia, NY 117495301
Telephone
631-444-9600Registry record last updated 29 May 2013.
Clinical trials
- Electrophysiological Effects of Late PCI After MI
Sponsor: University of Maryland, Baltimore
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
17 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Abbott LaboratoriesProgram year202513 payments
- Medtronic, Inc.Program year202523 payments
- Boston Scientific CorporationProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
60.8%Antiarrhythmic36.7%Dofetilide42%Amiodarone Hcl30%Multaq19%Mexiletine Hcl10%Part D<11 patientsBeta blocker18.1%Metoprolol Succinate100%Part D≥43 patients+ 2 more classes in this area
Blood & clotting
39.2%Factor Xa inhibitor39.2%Eliquis89%Xarelto11%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2005–2006 per NIH RePORTER. The latest:
- Arrhythmia Assessment Core Lab for IMMEDIATE Trial
State University New York Stony Brook
FY2006$135,430U01HL077822 - Arrhythmia Assessment Core Lab for IMMEDIATE Trial
State University New York Stony Brook
FY2005$45,320U01HL077822
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Effect of low dose colchicine on long term recurrence after atrial fibrillation ablation
International Journal of Cardiology
2025 - Atrial Fibrillation Catheter Ablation and Rhythm Control in Patients With Sickle Cell Disorders: A Propensity Score–Matched Analysis
Journal of the American Heart Association
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Gerald Smaldone, MD, PhD
Stony Brook Medicine
Nand Wadhwa, MD
Stony Brook Medicine
Steven Weissbart
Stony Brook Medicine
Sonya Marcus, MD
Stony Brook Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”